---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-365132"
form_type: "8-K"
ticker: "PBLS"
cik: "0001657677"
company_name: "Parabilis Medicines, Inc."
filed_at: "2026-08-25T20:10:15+00:00"
generated_at: "2026-08-25T20:11:27.694994+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Parabilis Medicines appoints Craig Tendler to board as independent Class II director

## Summary
- Board expanded to nine; Craig Tendler, M.D., appointed Class II director on Aug 22, 2026, term to 2028.
- Receives stock option for 20,294 shares at $39.36/share, vesting monthly over 3 years.
- Annual retainer of $40,000 for board plus $7,500 for Science & Technology Committee service.
- Tendler brings 30+ years oncology development incl. two decades at J&J; joins Science & Technology Committee.

## SEC filing metadata
- accession: 0001193125-26-365132
- form_type: 8-K
- ticker: PBLS
- cik: 0001657677
- company_name: Parabilis Medicines, Inc.
- filed_at: 2026-08-25T20:10:15+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1657677/000119312526365132/0001193125-26-365132-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1657677/000119312526365132/ck0001657677-20260822.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-365132
- JSON: https://secwatch.observer/filing/0001193125-26-365132.json
- Plain text: https://secwatch.observer/filing/0001193125-26-365132.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.